Precise ablation therapy for primary liver cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

YAN Yuzheng , XIAO Sijie ,  MA Kuansheng

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Army Medical University , Chongqing 400038, P. R. China;

Corresponding author：

MA Kuansheng, Email: kuanshengma@outlook.com

Keywords：

primary liver cancer; radiofrequency ablation; precise therapy

DOI：

10.7507/1007-9424.202410011

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In 2022, there were 367.7 thousands new cases and 316.5 thousands deaths of primary liver cancer in China. Radiofrequency ablation (RFA) is one of the radical treatments for liver cancer. It has the characteristics of definite curative effect, minimal invasion and low cost. In patients with early liver cancer, the curative effect is similar to surgical resection. The concept and practice of precision surgery provide new ideas for improving the efficacy of RFA. Based on the RFA treatment experience of more than ten thousand cases, the author’s team has carried out research on the precise ablation treatment of primary liver cancer. Now, the author will combine the existing literature and our team’s experience to discuss the application and prospect of the precise surgery concept in RFA treatment.

Citation： YAN Yuzheng, XIAO Sijie, MA Kuansheng. Precise ablation therapy for primary liver cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2024, 31(12): 1430-1433. doi: 10.7507/1007-9424.202410011 Copy

1.	中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版). 中华消化外科杂志, 2024, 23(4): 429-478.
2.	冯凯, 马宽生, 别平. 射频消融在肝细胞肝癌根治性治疗中的临床价值. 中国普外基础与临床杂志, 2014, 21(2): 150-155.
3.	Xu XL, Liu XD, Liang M, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology, 2018, 287(2): 461-472.
4.	董家鸿, 张宁. 精准外科. 中华外科杂志, 2015, 53(5): 321-323.
5.	樊嘉, 高强. 肝癌诊疗新进展: 指南引领规范创新赋能精准. 中华消化外科杂志, 2024, 23(2): 197-203.
6.	Li C, Wang Q, Zou M, et al. A radiomics model based on preoperative gadoxetic acid-enhanced magnetic resonance imaging for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma. Front Oncol, 2023, 13: 1164739. doi: 10.3389/fonc.2023.1164739.
7.	蒋涵羽, 陈卫霞. 浅析肝脏影像报告及数据系统在肝细胞癌诊治中的关键应用及挑战. 中国普外基础与临床杂志, 2024, 31(3): 272-277.
8.	Jiang YQ, Wang ZX, Deng YN, et al. Efficacy of hepatic resection vs. radiofrequency ablation for patients with very-early-stage or early-stage hepatocellular carcinoma: A population-based study with stratification by age and tumor size. Front Oncol, 2019, 9: 113. doi: 10.3389/fonc.2019.00113.
9.	Zhang K, Jiang L, Jia Z, et al. Radiofrequency ablation plus devascularization is the preferred treatment of hepatocellular carcinoma with esophageal varices. Dig Dis Sci, 2015, 60(5): 1490-1501.
10.	Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol, 2020, 72(2): 262-276.
11.	盛思满, 陈闯, 陈小宇, 等. 钆塞酸二钠增强磁共振成像在肝细胞癌大体形态分型中的应用价值. 中国普外基础与临床杂志, 2023, 30(7): 814-819.
12.	Liu J, Guo Y, Sun Y, et al. Three-dimensional ultrasound fusion imaging in precise needle placement for thermal ablation of hepatocellular carcinoma. Int J Hyperthermia, 2024, 41(1): 2316097. doi: 10.1080/02656736.2024.2316097.
13.	Shindoh J, Makuuchi M, Matsuyama Y, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol, 2016, 64(3): 594-600.
14.	杨世忠, 冯晓彬, 董家鸿. 精准外科理念指导下的肝癌外科治疗. 精准医学杂志, 2018, 33(3): 189-192,196.
15.	李璟寰, 王艳红. 射频消融治疗肝癌研究概况. 中华临床医师杂志(电子版), 2013, 7(8): 3526-3530.
16.	Ikeda K, Osaki Y, Nakanishi H, et al. Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma. Oncology, 2014, 87 Suppl 1: 73-77.
17.	周俭, 樊嘉, 肖永胜. 肝细胞癌门静脉癌栓形成机制. 实用肿瘤杂志, 2009, 24(5): 425-428.
18.	Xu EJ, Lv SM, Li K, et al. Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia, 2018, 34(6): 870-876.
19.	蔡建强, 赵宏, 陈晓. 肝癌综合治疗新格局. 中华消化外科杂志, 2024, 23(2): 204-208.
20.	Wang X, Liu G, Chen S, et al. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis. Int J Hyperthermia, 2021, 38(1): 1519-1528.
21.	Cheng AL, Hsu C, Chan SL, et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol, 2020, 72(2): 307-319.
22.	Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol, 2021, 7(1): 113-123.
23.	Feng X, Xu R, Du X, et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol, 2014, 109(12): 1891-1899.
24.	Kudo M. Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 update. Liver Cancer, 2020, 9(6): 640-662.
25.	中华医学会超声医学分会介入诊疗学组, 中国医药教育协会介入微创治疗专委会纳米刀肿瘤消融学会. 超声引导肝癌不可逆电穿孔消融治疗临床实践指南(2023版). 中华超声影像学杂志, 2023, 32(12): 1013-1020.

1. 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版). 中华消化外科杂志, 2024, 23(4): 429-478.
2. 冯凯, 马宽生, 别平. 射频消融在肝细胞肝癌根治性治疗中的临床价值. 中国普外基础与临床杂志, 2014, 21(2): 150-155.
3. Xu XL, Liu XD, Liang M, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology, 2018, 287(2): 461-472.
4. 董家鸿, 张宁. 精准外科. 中华外科杂志, 2015, 53(5): 321-323.
5. 樊嘉, 高强. 肝癌诊疗新进展: 指南引领规范创新赋能精准. 中华消化外科杂志, 2024, 23(2): 197-203.
6. Li C, Wang Q, Zou M, et al. A radiomics model based on preoperative gadoxetic acid-enhanced magnetic resonance imaging for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma. Front Oncol, 2023, 13: 1164739. doi: 10.3389/fonc.2023.1164739.
7. 蒋涵羽, 陈卫霞. 浅析肝脏影像报告及数据系统在肝细胞癌诊治中的关键应用及挑战. 中国普外基础与临床杂志, 2024, 31(3): 272-277.
8. Jiang YQ, Wang ZX, Deng YN, et al. Efficacy of hepatic resection vs. radiofrequency ablation for patients with very-early-stage or early-stage hepatocellular carcinoma: A population-based study with stratification by age and tumor size. Front Oncol, 2019, 9: 113. doi: 10.3389/fonc.2019.00113.
9. Zhang K, Jiang L, Jia Z, et al. Radiofrequency ablation plus devascularization is the preferred treatment of hepatocellular carcinoma with esophageal varices. Dig Dis Sci, 2015, 60(5): 1490-1501.
10. Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol, 2020, 72(2): 262-276.
11. 盛思满, 陈闯, 陈小宇, 等. 钆塞酸二钠增强磁共振成像在肝细胞癌大体形态分型中的应用价值. 中国普外基础与临床杂志, 2023, 30(7): 814-819.
12. Liu J, Guo Y, Sun Y, et al. Three-dimensional ultrasound fusion imaging in precise needle placement for thermal ablation of hepatocellular carcinoma. Int J Hyperthermia, 2024, 41(1): 2316097. doi: 10.1080/02656736.2024.2316097.
13. Shindoh J, Makuuchi M, Matsuyama Y, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol, 2016, 64(3): 594-600.
14. 杨世忠, 冯晓彬, 董家鸿. 精准外科理念指导下的肝癌外科治疗. 精准医学杂志, 2018, 33(3): 189-192,196.
15. 李璟寰, 王艳红. 射频消融治疗肝癌研究概况. 中华临床医师杂志(电子版), 2013, 7(8): 3526-3530.
16. Ikeda K, Osaki Y, Nakanishi H, et al. Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma. Oncology, 2014, 87 Suppl 1: 73-77.
17. 周俭, 樊嘉, 肖永胜. 肝细胞癌门静脉癌栓形成机制. 实用肿瘤杂志, 2009, 24(5): 425-428.
18. Xu EJ, Lv SM, Li K, et al. Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia, 2018, 34(6): 870-876.
19. 蔡建强, 赵宏, 陈晓. 肝癌综合治疗新格局. 中华消化外科杂志, 2024, 23(2): 204-208.
20. Wang X, Liu G, Chen S, et al. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis. Int J Hyperthermia, 2021, 38(1): 1519-1528.
21. Cheng AL, Hsu C, Chan SL, et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol, 2020, 72(2): 307-319.
22. Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol, 2021, 7(1): 113-123.
23. Feng X, Xu R, Du X, et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol, 2014, 109(12): 1891-1899.
24. Kudo M. Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 update. Liver Cancer, 2020, 9(6): 640-662.
25. 中华医学会超声医学分会介入诊疗学组, 中国医药教育协会介入微创治疗专委会纳米刀肿瘤消融学会. 超声引导肝癌不可逆电穿孔消融治疗临床实践指南(2023版). 中华超声影像学杂志, 2023, 32(12): 1013-1020.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Precise ablation therapy for primary liver cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content